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1. Current literature highlights
1.1. Non-symmetrical cyclic urea inhibitors of HIV-1
protease
The aspartic protease of the human immunodeﬁciency
virus type 1 (HIV-1) cleaves the viral gag-pol fusion precur-
sor polyprotein into active viral structural proteins and
replicative enzymes such as reverse transcriptase, endonu-
clease and integrase. This protease is an important target
for the design of speciﬁc antiviral agents as it plays this
essential role in the maturation of HIV-1 particles and viral
replication. Unfortunately, constant viral RNA mutations
and the ability of HIV-1 to rapidly generate drug-resistant
protease mutants requires a continuing evolution of new,
more potent protease inhibitors active against a wider spec-
trum of aspartic protease mutant forms.
Cyclic ureas of general structure (i) have been reported to
constitute a new class of potent non-peptidic inhibitors of
aspartic protease. A fundamental feature of these cyclic
urea inhibitors is the carbonyl oxygen that mimics hydro-
gen-bonding of the key structural water molecule present
in the active site of the aspartic protease. The presence of
this structural water diﬀerentiates the retroviral aspartic
protease from the human aspartic proteases pepsin and
rennin. Recent work in this area has employed computer-
assisted combinatorial chemistry methods to design, focus,
and screen in silico a virtual library of non-symmetrically
P1/P1 0 and P2/P2 0 substituted cyclic urea inhibitors.1
This work centred around deriving a small, highly focussed
library subset containing analogues with substituted aryl
side chains that were predicted by computational tech-
niques to provide inhibition constants (Ki) in the low
picomolar range, as well as a wide range of lipophilicity,
and water solubility. These properties predicted that the
virtual compounds possessed the potential to be developed
into antiviral agents. A set of structural ﬁlters and penalties
were introduced to reduce the number of commercially
available monomers employed in the virtual library gener-
ation. Speciﬁcally, 11 diﬀerent descriptors related to shape,
size, polarity, hydrogen bonding, lipophilicity, solubility,
and conformational ﬂexibility, relevant to the match be-
tween the monomers and the characteristics of the S3 to
S3 0 speciﬁcity pockets of the aspartic protease binding site
were computed. Further reduction in the virtual library size
was achieved by subjecting all virtual analogues to docking
into a model of the aspartic protease receptor derived from
the crystal structure of PR–XV-638 complex. This analysis
provided 90 cyclic urea analogues with the highest pre-
dicted aspartic protease inhibition potencies: Ki* < 10 pM.
This work has yielded a small highly focussed virtual com-
binatorial subset of fully non-symmetrical cyclic ureas,
which contained potential lead compounds with high pre-
dicted inhibitory potencies against the wildtype form of
aspartic protease of HIV-1. The predicted inhibition
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constants of the new ‘leads’ are up to 2 orders of magnitude
lower than the Kis of the training set. One of the most po-
tent compounds predicted from this analysis was (ii) with a
predicted Ki of 0.5 pM. The subset also contains aspartic
protease inhibitors predicted to be endowed with a wide
range of properties such as aqueous solubility, lipophilicity,
number of hydrogen-bonding groups, and cell membrane
permeability rates that may allow discovery of a potent or-
ally administrable antiviral drug with favourable pharma-
cokinetic properties.
1.2. Inhibitors of Subgenomic Hepatitis C Virus RNA
Replication
Hepatitis C virus (HCV) infection continues to pose a sig-
niﬁcant world health problem: currently around 170 mil-
lion people carry the virus globally. Current treatments
of HCV infection are inadequate, and increasingly the
patient population is facing an array of medical complica-
tions, such as cirrhosis and hepatocellular carcinoma,
resulting from disease progression. Eﬀorts towards treat-
ment of HCV are impeded by the complex biology associ-
ated with the virus. HCV is not infectious in cell culture or
in small animal models, thereby presenting a signiﬁcant
challenge to the development of anti-HCV agents.
However, the recent introduction of the HCV replicon as-
say, a surrogate cell-based system in which replication of
subgenomic viral RNA can be studied, has provided an ad-
vance for drug discovery eﬀorts targeting HCV proteins.
This assay is validated by the observation that an inhibitor
of a viral enzyme, the NS3 protease, shows potency in this
system and also elicits a strong reduction in viral titre in a
clinical setting. Consequently the search for compounds
that eﬃciently block HCV replication in the replicon assay
has become an intense area of pharmaceutical research.
The non-structural region of the HCV genome encodes sev-
eral enzymes that are believed to play fundamental roles in
the viral life cycle, and are thus thought to be viable targets
for drug discovery eﬀorts. The NS5B protein is one of these
enzymes and has been characterised as the RNA polymer-
ase enzyme that catalyses the synthesis of both a comple-
mentary ()-stranded HCV RNA intermediate, and the
(+)-stranded viral genome itself. The absence of a func-
tional counterpart to NS5B in mammalian cells, where
DNA is usually the template during RNA transcription,
may favour the development of virally selective inhibitors.
Recent work provides an account of eﬀorts to optimise a
series of indole-N-acetamide inhibitors, typiﬁed by struc-
ture (iii) toward compounds that show improved cell-based
potency and a suitable overall proﬁle for further develop-
ment as anti-HCV agents.2
A small library of 36 compounds based on the pharmaco-
phoric template in compound (iii) was synthesised as sin-
gletons in solution, using polymer-bound reagent and
scavenger resins during synthesis greatly facilitating work-
up by a simple ﬁltration. The compounds synthesised were
assessed for activity against the puriﬁed DC55 NS5B
enzyme (IC50) in the presence of heterogenic template
RNA. Inhibition of replication of subgenomic HCV
RNA was measured in HUH-7 cells. From this biological
screening, one of the most potent compounds isolated
was (iv) which possessed an IC50 of 7 nM.
Oﬀ-target activity at the pregnane X receptor (PXR) was
observed with many inhibitors discovered. However, fur-
ther optimisation was able to eliminate this unwanted oﬀ-
target activity. One of the most potent compounds against
the DC55 NS5B enzyme obtained (v) possessed an EC50 of
127 nM in a cell based assay, and was clean against PXR.
Inhibitors such as (v) have also displayed encouraging
pharmacokinetic properties in both rat and dog models.
This proﬁle, together with the eﬃcacy shown by (v) when
the replicon assay is performed in the presence of human
serum, highlights the potential of this structural series for
the development of novel anti-HCV agents.
2. A summary of the papers in this month’s issue
2.1. Solid-phase synthesis
A new strategy towards the eﬃcient solid phase synthesis of
functionalised cyclopeptides, that present considerable
interest for the development of nanodevices devoted to
tumour imaging or drug delivery, has been developed.3
2.2. Solution-phase synthesis
The total synthesis of the histone deacetylase inhibitor spiru-
chostatin A was undertaken as a prelude to the prepara-
tion of a combinatorial library of analogues. Two key
reactions used were an asymmetric acetate aldol reaction
using a Zr-enolate and macrolactonisation using the Shiina
method.4
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A palladium-catalysed parallel synthesis of bis-hetero(aryl)
ketones with two further synthetic steps allowing easy entry
to 3,3-di(hetero)arylpropylamines has been described.5
A tetrasaccharide and an analogous 1,2-linked compound
were comparatively synthesised in solution and on a solu-
ble polyethyleneglycol support. The merits and shortcom-
ings of oligosaccharide syntheses on MPEG are discussed.6
2.3. Scaﬀolds for combinatorial libraries
No papers this month.
2.4. Solid-phase supported reagents
A PEG-supported quaternary ammonium salt has been
shown to be an eﬃcient and recyclable homogeneous cata-
lyst for solvent-free synthesis of cyclic carbonates from car-
bon dioxide and epoxides under supercritical conditions.
Supporting Bu4NBr on soluble polymer PEG6000 en-
hances the catalytic activity and the workup procedure is
straightforward.7
Catalytic asymmetric etheriﬁcation of cycloalkenyl esters
with phenolic nucleophiles was achieved in water as the
sole reaction medium under heterogeneous conditions by
using a PS-PEG resin-supported palladium–imidazoindole-
phosphine complex.8
2.5. Novel resins, linkers and techniques
Use of a semicarbazide resin for the solid-phase prepara-
tion of peptide ketones and aldehyde has led to optimal re-
sults in terms of both purity of the ﬁnal product and overall
yield. The resin was prepared by activation of the commer-
cial available aminomethyl polystyrene with CDI at room
temperature, followed by treatment with tert-butyl
carbazate.9
Quality control of solid-phase synthesis has been achieved
by the use of pulse saturation transfer/magic angle spin-
ning (PST/MAS). This technique was highly eﬀective for
enhancing the MAS 13C NMR of the inter-mobile region
of polymer supported organic compounds.10
A sixteen component array of acid–base and metal ion sen-
sors has been synthesised and covalently immobilised onto
a transparent cellulose-based membrane. pH and metal ion
optical sensing properties of the sixteen component array
have been tested using high-throughput screening based
on digital imaging analysis.11
2.6. Library applications
The ﬁrst solid phase synthesis of the important anthelmin-
tic praziquantel has been described, and the method may
be extended to the synthesis of libraries of urgently needed
replacements for this drug.12
Convergent, parallel synthesis of a series of b-substituted
1,2,4-oxadiazole butanoic acids as potent and selective
avb3 integrin receptor antagonists has been described.13
As part of the optimisation process of a lead compound, a
focussed library of diversely substituted pyridazin-3(2H)-
ones containing 3-oxo-3-phenylprop-1-en-1-yl or 3-phenyl-
prop-2-enoyl fragments has been obtained and evaluated as
antiplatelet agents.14
A new class of Aurora-A inhibitors based on a bicyclic tet-
rahydropyrrolo[3,4-c]pyrazole scaﬀold have recently been
described. A solution phase synthesis protocol and early
parallel expansion of CDK2/cyclin A–E inhibitors belong-
ing to the same chemical class have been reported.15
A suitable solid-phase approach, based on Fmoc/tBu meth-
odology and on the use of 2-chlorotrityl resin, has allowed
a rapid and eﬃcient preparation of new gly-pro-glu (GPE)
analogues.16
A facile, dry media procedure has been developed for the
synthesis of a new class of ﬂuorine-containing compounds
using basic alumina as solid support. The synthesised com-
pounds have been screened in vitro for anti-fungal activity
against Rhizoctonia solani, Fusarium oxysporum and Col-
lectotrichum capsici, and most of the compounds have
shown good activity against these pathogens.17
Automated solid-phase synthesis has been used for the
preparation of antiprotozoal di- and trisubstituted 5 0-carb-
oxamidoadenosine derivatives by using a safety-catch ap-
proach, and this allowed the construction of two
representative combinatorial libraries. Their antiprotozoal
evaluation identiﬁed two compounds with promising activ-
ity against Trypanosoma brucei rhodesiense and chloro-
quine resistant Plasmodium falciparum.18
Highly modular tridentate Schiﬀ base ligands arising from
enantiopure epoxyalcohols have been prepared and evalu-
ated in catalysis using parallel methods. The key structural
motifs and experimental parameters have been identiﬁed,
allowing high enantioselectivities in the titanium-catalysed
trimethylsilyl cyanide addition to aldehydes.19
Lysine acetylation of human tumour suppressor p53 in re-
sponse to cellular stress signals is required for its function
as a transcription factor that regulates cell cycle arrest,
senescence, or apoptosis. Small molecules, discovered in
target structure-guided nuclear magnetic resonance spec-
troscopy screening of a focused chemical library, have been
shown to block lysine 382-acetylated p53 association with
the bromodomain of the coactivator CBP, an interaction
essential for p53-induced transcription of the cell cycle
inhibitor p21 in response to DNA damage.20
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